EMA Withdrawn: Skysona (elivaldogene autotemcel) — bluebird bio (Netherlands) B.V.

View source ↗

Summary

EMA has withdrawn Skysona (elivaldogene autotemcel) from the market in the Netherlands for adrenoleukodystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenoleukodystrophy

Drugs mentioned

• Skysona (elivaldogene autotemcel)

Snippet

Status: Withdrawn. Therapeutic area: Adrenoleukodystrophy. MAH: bluebird bio (Netherlands) B.V.. Decision date: 18/11/2021